Non–Small-Cell Lung Cancer: Questions and Answers on Using Mutation-Driven Therapy in Practice

Program Description & Educational Objectives

This activity addresses questions submitted by US-based oncologists in response to an electronic survey designed to assess specific educational needs regarding management of non–small-cell lung cancer (NSCLC).

Upon completion of this activity, participants should be better able to:

  • Apply recent clinical data and evidence-based guidelines on testing for driver mutations in patients with NSCLC
  • Discuss the emerging “single-driver mutation” treatment paradigm for NSCLC, specifically with regard to ALK inhibition
  • Evaluate the safety and efficacy of ALK inhibition, based on most current available data from studies in NSCLC

Target Audience

This activity has been designed to meet the educational needs of oncologists and other healthcare professionals who care for patients with NSCLC.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no pre-requisites and there is no fee to participate in this activity or to receive CME credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Internet
Release and Expiration Dates: March 13, 2012 - March 12, 2013
Time to Complete: 15 minutes

Faculty & Disclosure / Conflict of Interest Policy

In accordance with ACCME requirements, the University of Florida College of Medicine has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced.

Faculty Reviewer

Howard (Jack) West, MD
Medical Oncologist
Medical Director, Thoracic Oncology Program
Swedish Cancer Institute
Seattle, Washington

Howard (Jack) West, MD, currently has no financial interests/relationships or affiliations in relation to this activity.

CME Reviewer

Thomas J. George, MD, FACP
Division of Hematology/Oncology
Assistant Professor
Director, Gastrointestinal Oncology Program
Associate Director, Fellowship Training Program
University of Florida
Gainesville, Florida

Thomas J. George, MD, FACP, currently has no financial interests/relationships or affiliations in relation to this activity.

Content Director

Annette Wiggins
Answers in CME, Inc.

Annette Wiggins currently has no financial interests/relationships or affiliations in relation to this activity.

Sponsorship, Credit & Support

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the University of Florida College of Medicine and Answers in CME. The University of Florida College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The University of Florida College of Medicine designates this enduring material for a maximum of 0.25 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This CME activity is jointly sponsored by the University of Florida College of Medicine and Answers in CME.

This activity is supported by an educational grant from Bristol-Myers Squibb

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports.

Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.